Core Viewpoint - The E Fund Healthcare Industry Mixed A Fund (110023) reported a profit of 535 million yuan in Q2 2025, with a weighted average profit per fund share of 0.4323 yuan, and a net value growth rate of 12.16% during the reporting period [3] Fund Performance - As of July 18, the fund's unit net value was 4.524 yuan, with a recent three-month net value growth rate of 34.04%, ranking 47 out of 138 comparable funds [4] - The fund's six-month net value growth rate was 54.03%, ranking 48 out of 138, and the one-year growth rate was 51.05%, ranking 46 out of 133 [4] - Over the past three years, the fund achieved a net value growth rate of 52.38%, ranking 7 out of 107 [4] Risk and Return Metrics - The fund's Sharpe ratio over the past three years was 0.4532, ranking 17 out of 105 comparable funds [9] - The maximum drawdown over the past three years was 24.99%, with the worst quarterly drawdown occurring in Q1 2021 at 24.73% [11] Investment Strategy - The fund underwent significant portfolio adjustments during the reporting period, reducing holdings in sectors like CXO and IVD, while concentrating investments in the innovative drug sector, based on a thorough analysis of the prospects for China's innovative drug industry [3] Fund Holdings - The fund's average stock position over the past three years was 92.35%, compared to an average of 86.91% for comparable funds, reaching a peak of 94.24% at the end of H1 2023 [14] - As of Q2 2025, the fund's top ten holdings included companies such as Heng Rui Medicine, Recbio Technology, and BeiGene, with a concentration exceeding 60% for the top ten holdings over the past two years [18] Fund Size - As of the end of Q2 2025, the fund's total size was 3.944 billion yuan [15]
易方达医疗保健行业混合A：2025年第二季度利润5.35亿元 净值增长率12.16%
Sou Hu Cai Jing·2025-07-21 01:45